187 related articles for article (PubMed ID: 37817743)
1. The effectiveness of CFTR modulators in people with CF and rare mutations: A real-world study.
Hanger S; Felton I; Ukor EF; Bowman E; Caldwell C; Banya W; Madge S; Jones AL; Simmonds NJ
Pediatr Pulmonol; 2024 Jan; 59(1):221-224. PubMed ID: 37817743
[No Abstract] [Full Text] [Related]
2. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis.
Derichs N
Eur Respir Rev; 2013 Mar; 22(127):58-65. PubMed ID: 23457166
[TBL] [Abstract][Full Text] [Related]
3. Current state of CFTR modulators for treatment of Cystic Fibrosis.
Despotes KA; Donaldson SH
Curr Opin Pharmacol; 2022 Aug; 65():102239. PubMed ID: 35609385
[TBL] [Abstract][Full Text] [Related]
4. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
Mayer-Hamblett N; Boyle M; VanDevanter D
Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
[TBL] [Abstract][Full Text] [Related]
5. CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France.
Regard L; Martin C; Burnet E; Da Silva J; Burgel PR
Cells; 2022 May; 11(11):. PubMed ID: 35681464
[TBL] [Abstract][Full Text] [Related]
6. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
7. Emerging medicines to improve the basic defect in cystic fibrosis.
Fajac I; Sermet-Gaudelus I
Expert Opin Emerg Drugs; 2022 Sep; 27(3):229-239. PubMed ID: 35731915
[TBL] [Abstract][Full Text] [Related]
8. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ
Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995
[TBL] [Abstract][Full Text] [Related]
9. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Ong T; Ramsey BW
Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
[TBL] [Abstract][Full Text] [Related]
10. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
11. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
Cuyx S; De Boeck K
Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
[TBL] [Abstract][Full Text] [Related]
12. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.
Kotha K; Clancy JP
Ther Adv Respir Dis; 2013 Oct; 7(5):288-96. PubMed ID: 24004658
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of cystic fibrosis treatment.
Carter SC; McKone EF
Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
[TBL] [Abstract][Full Text] [Related]
14. Ion Channel Modulators in Cystic Fibrosis.
Gentzsch M; Mall MA
Chest; 2018 Aug; 154(2):383-393. PubMed ID: 29750923
[TBL] [Abstract][Full Text] [Related]
15. Towards next generation therapies for cystic fibrosis: Folding, function and pharmacology of CFTR.
Bose SJ; Krainer G; Ng DRS; Schenkel M; Shishido H; Yoon JS; Haggie PM; Schlierf M; Sheppard DN; Skach WR
J Cyst Fibros; 2020 Mar; 19 Suppl 1(Suppl 1):S25-S32. PubMed ID: 31902693
[TBL] [Abstract][Full Text] [Related]
16. An update on new and emerging therapies for cystic fibrosis.
Hudock KM; Clancy JP
Expert Opin Emerg Drugs; 2017 Dec; 22(4):331-346. PubMed ID: 29264936
[TBL] [Abstract][Full Text] [Related]
17. Prenatal Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Promising Way to Change the Impact of Cystic Fibrosis.
Gómez-Montes E; Salcedo Lobato E; Galindo Izquierdo A; García Alcázar D; Villalain González C; Moral-Pumarega MT; Bustos Lozano G; Luna-Paredes C
Fetal Diagn Ther; 2023; 50(2):136-142. PubMed ID: 36996799
[TBL] [Abstract][Full Text] [Related]
18. Amphotericin B induces epithelial voltage responses in people with cystic fibrosis.
Chorghade RS; Kim BR; Launspach JL; Karp PH; Welsh MJ; Burke MD
J Cyst Fibros; 2021 May; 20(3):540-550. PubMed ID: 33309058
[TBL] [Abstract][Full Text] [Related]
19. Mutation-specific therapies and drug repositioning in cystic fibrosis.
Villella VR; Tosco A; Esposito S; Bona G; Raia V; Maiuri L
Minerva Pediatr; 2019 Jun; 71(3):287-296. PubMed ID: 30761820
[TBL] [Abstract][Full Text] [Related]
20. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
